[Federal Register Volume 75, Number 169 (Wednesday, September 1, 2010)]
[Notices]
[Page 53704]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-21818]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Use of Pentosan
Polysulfate To Treat Certain Conditions of the Prostate
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive patent license to practice the invention embodied in U.S.
Patent Application No. 10/209,331, filed July 30, 2002, which was
issued as U.S. Patent 6,828,309 on December 07, 2004, entitled, ``USE
OF PENTOSAN POLYSULFATE TO TREAT CERTAIN CONDITIONS OF THE PROSTATE,''
developed by Dr. Gary Striker (formerly of NIDDK) [HHS Ref. No. E-104-
1997/0-US-03], to Swati Spentose Private Limited, having a place of
business in Mumbai, India. The patent rights in this invention have
been assigned to the United States of America.
The contemplated exclusive license territory may be worldwide, and
the field of use may be limited to ``the use of pentosan polysulfate
for the treatment or prevention of benign prostatic hyperplasia.''
DATES: Only written comments and/or application for a license which are
received by the NIH Office of Technology Transfer on or before October
1, 2010 will be considered.
ADDRESSES: Requests for copies of the patents, inquiries, comments, and
other materials relating to the contemplated license should be directed
to: Suryanarayana Vepa, PhD, J.D., Licensing and Patenting Manager,
Office of Technology Transfer, National Institutes of Health, 6011
Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone:
301-435-5020; Facsimile: 301-402-0220; E-mail: [email protected].
SUPPLEMENTARY INFORMATION: This technology is a method for treating
Benign Prostatic Hyperplasia (BHP) using the oral medication pentosan
polysulfate (PPS). PPS is a well known, semi-synthetic polysaccharide
extracted from beech wood cellulose that is FDA approved for the
treatment of interstitial fibrosis. The current technology builds on
the surprising discovery that PPS can cause regression of scarring and
lesions in prostatic tissue. PPS reduces or eliminates both smooth
muscle cell proliferation and extracellular matrix deposition, and so
reduces the size of the prostate gland and decreases associated
obstructive symptoms.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 30 days
from the date of this published Notice, the NIH receives written
evidence and argument that establishes that the grant of the license
would not be consistent with the requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license in the prospective field of use filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive license. Comments and objections submitted
in response to this notice will not be made available for public
inspection, and, to the extent permitted by law, will not be released
under the Freedom of Information Act, 5 U.S.C. 552.
Dated: August 25, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development & Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-21818 Filed 8-31-10; 8:45 am]
BILLING CODE 4140-01-P